Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 5
Submit an article Journal homepage
7
Views
15
CrossRef citations to date
0
Altmetric
Research

Section Review Central & Peripheral Nervous Systems: 5-HT3 receptor antagonists

Ph Silverstone Clinical Psychopharmacology Research Unit, Department of Psychiatry, 1E7.44 Walter Mackenzie Health Sciences Centre, University of Alberta, Edmonton, Alberta, T6G 2B7, Canada
&
Aj Greenshaw Neurochemical Research Unit, Department of Psychiatry, 1E7.44 Walter Mackenzie Health Sciences Centre, University of Alberta, Edmonton, Alberta, T6G 2B7, Canada
Pages 471-481 | Published online: 29 Feb 2008

References to Primary Literature

  • DERKACH V, SURPRENANT A, NOTII RA: 5-HT3 receptors are membrane ion channels. Nature (1989) 339:706–708.
  • JACKSON MB, YAKEL JL: The 5-HT3 receptor channel Ann. Rev. Physiol. (1995) 57:447–468.
  • MARICQ AV, PETERSON AS, BRAKE AJ et al.: Primary structure and functional expression of the 5-HT3 recep-tor, a serotonin gated ion channeL Science (1991) 254:432–437.
  • MIYAKE A, MOCHIZUKI S, TAKEMOTO Y, AKUZAWA S: Molecular cloning of human 5-H1'3 receptor: heteroge-neity in distribution and function among species. Mol. Pharmacol. (1995) 48:407–416.
  • BOESS FG, MARTIN IL: Molecular biology of 5-HT receptors. Neuropharmacol. (1994) 33:275–317.
  • GADDUM JH, PICARELLI ZP: Two kinds of tryptamine receptor. Br. J. PharmacoZ (1957) 12:323–328.
  • KILPATRICK GJ, JONES BJ, TYERS MB: Identification and distribution of 5-HT3 receptors in rat brain using radii-oligand binding. Nature (1987) 330:746–748.
  • FOZARD JR, MOBAROK-ALI ATM: Receptors for 5-hy- droxytryptamine on the sympathetic nerves of the rabbit heart. Naunyn-Scbmiedeberg's Arch Pharmacol. (1978) 301:223–235.
  • GYERMEK L: A new class of 5-hydroxytryptarnine an-tagonists. J. Med. Chem. (1964) 7:280–284.
  • FOZARD JR, MOBAROK-ALI ATM: Blockade on neuronal tryptainine receptors by metaclopramide. Eur. J. Phar-macol. (1978) 49:109–112.
  • GYERMEK L: 5-HT3 receptors: pharmacologic and thempeutic aspects. J. Clin. Pbarmacol. (1995) 35:845–855.
  • BACHI A, HEAULME, M GUIDICDE A et al.: SR57277A: apotent and selective agonist at central and peripheral5-HT3 receptors in vitro and in vivo. Eur. J. Pharmacol. (1993) 237:299–309.
  • FORD APDW, CLARKE DE: The 5–1114 receptor. Med. Res. 0Rev. (1993) 13:633–662.
  • GREENSHAW AJ: Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential. Trends Pharamcol. Sci. (1993) 14:265–270.
  • MOULIGNIER A: Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic appli-cations. Rev. Neurol. (1994) 150:3–15.
  • LAUNAY JM, CALLBERT J, BONDOUX D et al.: Serotoninreceptors and therapeutics. Cell Mot Biol. (1994) 40:327–336.
  • MARTY M, POUILLART P, CHOL S et at: Comparison of the 5-hydroxytyrptamine 3 (serotonin) antagonist on-dansetron (GR38032F) with high-dose metaclopramide In the control of cisplatin-induced emesis. N. Eng.J. Med. (1990) 322:816–821.
  • TYERS MB: 5-HT3 receptors and the therapeutic poten-tial of 5-HT3 antagonists. 7herapie (1991) 46:431–435.
  • AAPRO MS: 5-HT3 receptor antagonists. Drugs (1991) 42:551–568.
  • GLAUM SR, PROUDFIT HK, NADERSON EG: 5-HT3 receptors modulate spinal nociceptvie reflexes. Brain Res. (1990) 510:12–16.
  • MELLER ST, LEWIS SJ, BRODY MJ et al.: Vagal afferent-me- diated inhibition of a nociceptive reflex by iv serotonin In the rat H: role of the 5-LIT receptor subtypes. Brain Res. (1992) 585:71–86.
  • ALFIAIDER AA,LEI SZ, WILCOX GL: Spinal 5-HT3 -mediated antinociception - possible release of GABA. J. Neurosci. (1991) 11:1881–1888.
  • SAWYNOK J, REID A: Spinal supersensitivity to 5-HT, 5-HT2 and 5-HT3 receptor agonists following 5,7-dihy-droxytryptamine. Eur. J. Pharmacol. (1994) 264:249–257.
  • KIA HK, MIQUEL M-C, MCKERNAN RM et al.: Localisation of 5-HT3 receptors in the rat spinal cord: irrumunohis-tochemistry and in situ hybridisation. Neuro Report (1995) 6:257–261.
  • SANGER GJ, WARDLE KA: Constipation evolved by 5-HT3-receptor antagonism: evidence for heterogeneous effi-cacy among different antagonists in guinea-pigs. J. Pharm. Pharmacol. (1994) 46:666–670.
  • YUAN SY, BORNSTEIN JC, FURNESS .113: Investigation of the role of 5-HT3 and 5-HT4 receptors in ascending and descending reflexes to the circular muscle of guinea-pig small intestine. Br. J. Pharmacol. (1994) 112:1095–1100.
  • BANNER SE, SANGER GJ: Differences between 5-HT3 receptor antagonists in modulation of visceral hy-persensitivity. Br. J. Pharmacol. (1995) 114:558–562.
  • MORTEAU 0, JULIA V, EECKHOUT C et al.: Influence of 5-HT3 receptor antagonists in visceror motor and no-ciceptive responses to rectal distension before and during experimental colitis in rats. Fundam. Clin. Phar-macol. (1994) 8:553: 562.
  • KISHIBAYASHI N, MIWA Y, HAYASHI II et al.: 5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of Irritable bowel syndrome. J. Med. Chem. (1993) 36:3286–3292.
  • PRIOR A, READ NW: Reduction of rectal sensitivity and postprandial motility by granisetron, a 5-11T3 receptor antagonist, in patients with irritable bowel syndrome (IBS). Gut (1990) 31:A1174.
  • MAXTON DG, HAIGH CG, WHORWELL PJ: Clinical trial ofondansetron, a selective 5-HT3 antagonist in irritable bowel syndrome (IBS). Gastroenterol. (1991) 100:A468.
  • CHAPPELLAS, BAY JM, BOTZUM GD et al.: Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine. Neuropharmacol. (1994) 33:509–513.
  • COUTURIER EGM, HERING R, FOSTER CA et al.: First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache (1991) 31:296–297.
  • LOISY C, BEORCHIA S, CENTONZE V et al.: Effects on migraine headache of MDL 72222, an antagonist at neuronal 5-HT receptors, double-blind, placebo-con-trolled study. Cepbalalgia (1985) 5:79–82.
  • FERRARI MD, WILKINSON M, HIRT D et al.: Efficacy of ICS 205-930 a novel 5-hydroxytriptamine-3 5-HT3 receptor antagonist in the prevention of migraine attacks: a complex answer to a simple question. Pain (1991) 45:283–292.
  • COSTALL B, DOMENEY AM, NAYLOR RJ, TYERS MB: Effectsof the 5-HT3 receptor antagonist GR38032F on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br. J. Pharmacol. (1987) 92:881–894.
  • PALFREYMAN MG, SORENSEN SM, BARON BM et al.: An-tipsychotic potential of 5-HT3 antagonists. In: Novel Antipsychotic Drugs. Meltzer HY (Ed). Raven, New York. (1992):211–223.
  • CARBONI E, ACQUAS E, LEONE P, DI CHIARA G: 5-HT3receptor antagonists block morphine- and nicotine- but not amphetamine-induced reward. Psychopharmacol. 97 (1989) 97:175-178.
  • HIGGINS GA, JOHARCHI N, NGUYEN P, SELLERS EM: Effectof the 5-HT3 receptor antagonists, MDL 72222 and ondansetron on morphine place conditioning. Psycho-pbarmacol. (1992) 106:315–320.
  • ARNOLD B, ALLISON K, IVANOVA S et al.: 5-HT3 receptor antagonists do not block nicotine induced hyperactiv-ity in rats. Psychopbarmacol. (1995) 119:213–221.
  • PEI Q, ETTERSTRON T,LESLIE RA et al.: 5-HT3 antagonists Inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur. J. Phar-macol. (1993) 230:63–68.
  • NEWCOMER JW, FAUSTMAN WO, ZIPURSKY RB et al.: Zacopride in schizophrenia: a single-blind serotonic type 3 antagonist triaL Arch. Gen. Psychiat. (1992) 49:751–752.
  • ACQUAS E, CARBONI E, GARAU L et al.: Blockade of acquisition of drug-conditioned place aversion by 5-HT3 antagonists. Psychopbarmacol. (1990) 100:459–463.
  • pApP M: Similar effects of diazepam and the 5-HT3 receptor antagonist ICS 205-930 on place aversion con-ditioning. Eur. J. Pharmacol. (1988) 151:321–324.
  • BELL DJ, FLETCHER A, GLENN BD et al.: Behavioural studies on WAY 100289, a novel 5-HT3 receptor antago-nist, in two animal models of anxiety. Eur. j Pharmacol. (1992) 218:327–333.
  • BLACKBURN 'EP, BAXTER GS, KENNETT GA et al.: BRL 46047A: A highly potent, selective and long-acting 5-HT3 receptor antagonist with anxiolytic-like properties. PsY-cbopharmacol. (1993) 110:257–264.
  • COSTALL B, NAYLOR RJ: The psychopharmacology of 5-HT3 receptors. Pharmacol. Toxicol. (1992) 71:401–415.
  • ARTAIZ I, ROMERO G, ZAZPE A et al.: The pharmacology of VA21137: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models. Psycho-pharmacol. (1995) 117:137–148.
  • NEVINS ME, ANTHONY EW: Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle re-sponse in the rat: evidence for different types of anxiolytic activity. J. Pharmacol. Exp. Trier. (1994) 268:248–268.
  • GOUDIE AJ, LEATHLEY MJ: Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine with-drawal in rats. Eur.J. Pharmacol. (1990) 185:179–186.
  • REZAZADCH SM, PRATHER PL, EMMETT-OGLESBY MW et al.: Evaluation on anxiolytic action of ondansetron in rats during withdrawal from chronic chlordiazepoxide. Ann. NY Acad. Sci. (1992) 264:472–473.
  • SAPHIER D, WELCH JE: 5-HT3 receptor activation in the rat increases adrenocortical secretion at the level of the central nervous system. Neurosci. Res. Commun. (1994) 14:167–173.
  • LECRUBIER V, PUECH AJ, AZCONA A et al.: A randomised double-blind placebo-controlled study of tropisetron inthe treatment of outpatients with generalised anxiety disorder. Psychopharmacol. (1993) 112:129–133.
  • SILVERSTONE PH, COWEN PJ: The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biol. Psychiat. (1994) 36:309–316.
  • MOSCONI M, CHIAMULERA C, RECCHIA G: New anx-iolytics in development. Int. J. din. Pharm. Res. (1993) 13:331–344.
  • LUCHELLI A, SANTAGOSTINO-BORBONE MG, BARBIERI A et al.: The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 recep-tors. Br.]. Pharmacol. (1995) 114:1017-1025. BLIER P, BOUCHARD C: Functional characterisation of a 5-HT(3)-receptor which modulates the release of 5-HT in the guinea pig brain. Br.J.Pharmacol. (1993) 108:13-22. FAN P: Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones. Br. J. Pharmacol. (1994) 112:741-744. FAN P: Inhibition of a 5-HT3 receptor-mediated current by the selective serotonin uptake inhibitor, fluoxetine. Neurosci. Lett. (1994) 173:210–212.
  • KOOYMAN AR, ZWART R, VANDERHEIJDEN PML et al.: Interaction between enantiomers of mianserin and 0RG3770 at 5-IIT3 receptors in cultures mouse neuroblastoma cells. Neuropharmacol (1994) 33:501–507.
  • MONGEAU R, DE MONTIGNY C, BLIER B: Activation of 5-HT3 receptors enhances the electrically evoked re-lease of [3H]noradrenaline in rat brain limbic struc-tures. Eur. J. Pharmacol. (1994) 256:269–279.
  • PONCELET M, PERIO A, SIMIAND J et al.: Antidepressant like effects of SR57227A, a 5-HT3 receptor agonist inrodents.]. Neural. Trans. (1995) 102:83–90.
  • CORRIGALL WA, COEN KM: Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205-930 and MDL 72222. Pharmacol. Biochem. Behav. (1994) 49:67–71.
  • LANE JD, PICKEING CL, HOOPER ML et al.: Failure of ondansetron to block the discriminative or reinforcing stimulus properties of cocaine in the rat. Drug Alcohol Depend. (1992) 30:151–162.
  • SILVERSTONE PH, OLDMAN B, JOHNSON B et al.: Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in volunteers. Int. Clin. Psychopharmacol(1992) 7:37–43.
  • JASINSKI DR, PRESTON KL, TESTA M et al.: Evaluation of the 5-HT3 antagonist ondansetron (0) for cocaine (C)-like activity and abuse potential NIDA Res. Monog. (1991) 105:515.
  • HIGGINS GA, WANG Y, CORRIGALL WA et al.: Influence of 5-HT3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin seff-administra-don in rats. Psychopharmacol. (1994) 114:611–619.
  • SELL LA, COWEN PJ, ROBSON PJ: Ondansetron and opiate craving: a novel pharmacological approach to addic-tion. Br.].Psychiat. (1995) 166:511–514.
  • ZACNY JP, APPELBAUM JL, LICHTOR JL et al.: Effects of 5-hydroxytryptamine 3 antagonist, ondansetron, on cigarette smoking, smoke exposure and mood in hu-mans. Pharmacol. Biochem. Behav. (1993) 44:387–391.
  • SELLERS EM, HIGGINS GA, SOBELL MB: 5-HT and alcohol abuse. Trends Pharmacol. Sci. (1992) 13:69–75.
  • SELLERS EM, TONCATTO T, ROMACH MK et al.: Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcoholism: Clin. Exp. Res. (1994) 18:879–885.
  • DOTY P, ZACNY JP, DE WIT FL Effects of ondansetron pre-treatment on acute responses to ethanol in social drinkers. Behav. Pharmacol. (1994) 5:461–469.
  • GRANT HA, HELLEVUO K, TABAKOFF B: The 5-HT3 an-tagonist MD-72222 exacerbates ethanol withdrawal sei-zures in mice. Alcoholism: din. Exp. Res. (1994) 18:410–414.
  • KOSTOWSKI W, DYR W, KRZASCIK P: The abilities of 5-HT3 receptor antagonist ICS 205-930 to inhibit alcohol preference and withdrawal seizures in rats. Alcohol (1993) 10:369–373.
  • BEARDSLEY PM, LOPEZ OT, GULLIKSON G et al.: Sero-tonin 5-HT3 antagonists fail to affect ethanol self-ad-ministration of rats. Alcohol (1994) 11:389–395.
  • BARNES JM, BARNES NM, COSTALL B et al.: 5-HT3 recep-tors mediate inhibition of acetylcholine release in cor-tical tissue. Nature (1989) 338:762–763.
  • DOMENEY AM, COSTALL B, GERRARD PA et al.: The effect of ondansetron on cognitive performance in the mar-moset. Pharmacol. Biochem. Behav. (1991) 38:169–175.
  • JOHNSON EM, INOUYE GT, EGLEN EM et al.: 5-HT3 receptor ligands lack modulatory influence of acetylcholine release in rat entorhinal cortex. Naunyn-Schmeid Arch Pharmacol. (1993) 347:241–247.
  • CONSOLO S, BERTORELLI R, RUSSI G et al.: Serotonergic facilitation of acetylcholine release in vivo from rat dorsal hippocampus via serotonin 5-HT3 receptors. J. Neurochem. (1994) 62:2254–2261,
  • PITSIKAS N, BRAMBILLA, BORSINI F: Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-in-duced amnesia in the rat in a spatial learning task Pharmacol. Biochem. Behav. (1994) 47:95–99.
  • REIKKINEN P JR, SIRVO J, REKKINEN P: Non-reversal ofscopolamine- or age-related EEG changes by ondan-setron, methysergide or alaproclate. Psychopharmacol. (1991) 103:567–570.
  • BRATT AM, KELLY E, DOMENEY AM et al.: Ondansetron fails to attenuate a scopolamine-induced deficit in a Stone maze task. Neuro. Report (1994) 5:1921–1924.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.